News Related to Negative Predictive Value

Related coverage linked through entity extraction aliases.

PARP inhibitors remain strongest in BRCA-mutant tumors as labels narrow

Apr 22, 2026

PARP inhibitors remain strongest in BRCA1/2-altered tumors as use beyond that group has been uneven. In June 2025, the FDA narrowed Zejula’s first-line ovarian maintenance indication to HRD-positive tumors only.

ctDNA Detection and CCR5 Inhibition Show Promise in Triple-Negative Breast Cancer

Mar 07, 2026

New research highlights circulating tumor DNA as a prognostic tool in early-stage triple-negative breast cancer, while leronlimab demonstrates long-term survival signals in heavily pretreated metastatic patients through CCR5 receptor blockade.